Association between HLA-class I and HLA-class II alleles and mycobacterium tuberculosis infection in Iraqi patients from Baghdad city.
Mycobacterium tuberculosis is an extremely successful pathogen that has the ability to modulate the host immune response on the level of innate and acquired types. (1,2) However, such modulation may be subjected to immunogenetic predisposition because it has been demonstrated that certain human infectious diseases occur more frequently among individuals carrying particular human leukocyte antigen (HLA) alleles. (3) HLA-associated susceptibility to infectious disease could be due to the inability of a particular HLA protein to be associated effectively with processed antigens from the pathogen, thereby limiting the capacity of the individual to mount an effective immune response against it. (4) Pulmonary tuberculosis (PT) is one of the infectious diseases that follow this manner. In patients with PT, positive associations have been reported between class I and II HLA alleles and the disease in different ethnic populations. (5) In this regard, certain HLA alleles (B*40 and DQB*0301) and haplotypes (A*2-DRB1*1502) are believed to be associated with disease susceptibly, (2,5-7) while a protective effect has also been suggested for other HLA alleles such as A*11 and B*57. (5,8) It has been concluded accordingly that HLA plays a great role in the pathogenesis of this pathogen. (3,9).
Consequently, we aimed to study the association between HLA alleles and PT in Iraqi patients, who referred to the Institute of Tuberculosis in Baghdad city.
Patients and Methods
After obtaining approval from the Iraqi Ministry of Health's Ethics Committee, a total of 105 Iraqi Arab patients of both genders (age range=16-63 years) were enrolled in the study. They referred to the Institute of Tuberculosis (Baghdad) for diagnosis and treatment. The diagnosis was based on clinical symptoms, X-ray chest examination, tuberculin reactivity test, and detection of acid fast bacilli by direct staining of sputum and culture. (10) For the purposes of comparison, 40 blood donors, age-, gender-, and ethnicity-matched, were also included and considered as a control group.
Venous blood (10 ml) was drawn in a Heparinized tube, and then it was subjected to a density gradient centrifugation using lymphoprep as a separating medium to collect lymphocytes. The collected cells were further separated into T and B lymphocytes using the nylon wool method. T cells were phenotyped for HLA-class I alleles (A and B), while B cells were employed in the phenotyping of HLA-class II alleles (DR and DQ) in the microlymphocytotoxicity test, (11) using a panel of monoclonal antibodies (Biotest Company, Germany) that were able to recognize 8 A, 20 B, 10 DR, and 4 DQ HLA antigens.
Significant variations of HLA alleles between the patients and controls were assessed using the Fisher exact probability (P), and the P value was corrected for the number of antigens tested at each locus. The correction factors were 8, 20, 10, and 4 for HLA-A, -B, -DR, and -DQ loci, respectively. The results were presented in terms of observed numbers, percentage frequencies, odds ratio (OR), etiological fraction (EF), and preventive fraction (PF). The latter two estimations were calculated when the OR values were >1 (positive association) and <1 (negative association), respectively. The 95% confidence intervals (C.I.) of the OR were also given. The mathematical calculations of these estimations were carried out using the statistical package PEPI, version 4.0.
The observed numbers and percentage frequencies of HLA-class I (A and B) and -class II (DR and DQ) alleles are given in tables 1 and 2, respectively, while alleles showing significant variations between the PT patients and controls are given in table 3. As is shown in the tables, the frequencies of B18 (16.2 vs. 2.5%; OD = 7.53) and DR1 (51.4 vs. 10.0%; OD = 9.53) alleles were significantly increased in the patients as compared with the controls, while B5 (6.7 vs. 25.0%), DR8 (1.9 vs. 17.5%), and DQ3 (11.4 vs. 45.0%) alleles were significantly decreased. However, a significant corrected level was maintained for only DR1, DR8, and DQ3 alleles (Pc = 1.9 x [10.sup.-5], 0.02 and 1.0 x [10.sup.-4], respectively).
Several studies have been carried out to understand whether the susceptibility and/or immune response to M. tuberculosis is associated with HLA phenotype and/or controlled by the genes that are linked to MHC. (8,9,12) Studies have also been conducted to find relevant T-cell epitopes of M. tuberculosis antigens and their peptides in the context of HLA-DR molecules and to define their usefulness for diagnosis or vaccine design. (13) For HLA-class I alleles, none of the inspected alleles maintained a significant corrected variation between the patients and controls, although B8 was increased and B5 was decreased in the patients. However, other investigators have reported different positive and negative associations. Hans et al. (14) considered A11 and B15 alleles as risk factors for tuberculosis in Americans. On the other hand, Lewinsohn et al. (15) stated that HLA-B alleles were served as the dominant MHC class I restricting molecules for anti-mycobacterium-specific CD8+ T cell responses measured in CD8+ T cells from patients with PT. These results were in agreement with the previous studies that approved the association between certain HLA types and infectivity and tuberculosis. (16) Nevertheless, Vijaya et al. (17) suggested that B52 (split of B5) had a negative association (protective effect) with PT, a suggestion that chimes in with the findings of the present study.
The present study also revealed that DR1 was significantly higher in the PT patients than the controls; an observation that may suggest that this allele is a PT predisposing factor in Iraqis, especially when we consider an OR of 9.53 and EF value of 0.46. In contrast, DR8 and DQ3 might be associated with a protective effect. In this regard, it has been demonstrated that an altered memory response to M. tuberculosis in DR1 negative patients was observed in favor of curing. (18) The same authors reported that DR8 was associated with resistance to PT, as was the case in the present study. However, further inconsistent observations have also been documented. DRB1*1302 phenotype was significantly associated with PT occurring at a significantly higher allele frequency in cases by comparison with controls and especially in haplotype containing DQB1*0602/3. (19) DQB1*0301-0304 phenotype was also significantly associated with PT, especially when it occurred in haplotype with DRB1*1101-1121. (9) In another study, results indicated that DRB1*0803 and DQB1*0601 were found to be associated with PT disease progression, development of drug resistance, and disease severity in Koreans. (20) In South Africa, DRB1*1302 and DQB1*0301 to -0304 were apparently associated with active PT compared to control individuals lacking these alleles. (3) The prevalence of HLA-DRB1*0401 and HLA-DRB1*0801 was significantly decreased in Mexican patients with PT compared to their prevalence in healthy controls. (21)
In Iraqi PT patients, DR1 might be considered as an indicative marker of disease susceptibility, while DR8 and DQ3 are associated with resistance against PT development. However, further studies are required to confirm these associations, and certainly a much clear picture will be gathered if HLA typing is carried out at the molecular level and with a larger number of controls.
Conflict of Interest: None declared.
(1) David GR. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev. 2011;240:252-68. PubMed PMID: 21349098. PubMed Central PMCID: PMC3174472.
(2) Harriff MJ, Purdy GE, Lewinsohn DM. Escape from the Phagosome: the explanation for MHC-I processing of mycobacterial antigens. Front Immunol. 2012;3:40. PubMed PMID: 22566923. PubMed Central PMCID: PMC3342008.
(3) Lombard Z, Dalton DL, Venter PA, Williams RC, Bornman L. Association of HLA-DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of South Africa. Human Immunol. 2006;67:643-54. doi: 10.1016/j.humimm.2006.04.008. PubMed PMID: 16916662.
(4) Louie LG, Hartogensis WE, Jackman RP, Schultz KA, Zijenah LS, Yiu CH, et al. Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leukocyte antigen variation. J Infect Dis. 2004;189:1084-90. PubMed PMID: 14999612.
(5) Kettaneh A, Seng L, Tiev KP, Toledano C, Fabre B, Cabane J. Human leukocyte antigens and susceptibility to tuberculosis: a meta-analysis of case-control studies. Int J Tuberc Lung Dis. 2006;10:717-25. PubMed PMID: 16848331.
(6) Grotzke JE, Harriff MJ, Siler AC, Nolt D, Delepine J, Lewinsohn DA, et al. The mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle. PLoS Pathog. 2009;5:e1000374. PubMed PMID: 19360129. PubMed Central PMCID: PMC2661020.
(7) Raghavan S, Selvaraj P, Swaminathan S, Alagarasu K, Narendran G, Narayanan PR. Haplotype analysis of HLA-A, -B antigens and -DRB1 alleles in south Indian HIV-1-infected patients with and without pulmonary tuberculosis. Int J Immunogenet. 2009;36:129-33. doi: 10.1111/j.1744-313X.20 0 9.00 8 35.x. PubMed PMID: 19392836.
(8) Contini S, Pallant M, Vejbaesya S, Park M, Chierakul S, Kim S, et al. A model of phenotypic susceptibility to tuberculosis: deficient in Silico selection of mycobacterium tuberculosis epitopes by HLA alleles. Sarcoidosis vasc and diffuse lung dis. 2008;25:21-8. PubMed PMID: 19070257.
(9) Jagannathan L, Chaturvedi M, Satish B, Satish KS, Desai A, Subbakrishna DK, et al. HLA-B57 and Gender Influence the Occurrence of tuberculosis in HIV infected people of south India. Clin Develop Immunol. 2011;2011:549023. doi: 10.1155/2011/549023. PubMed PMID: 21876708.
(10) Gaseitsiwe S, Valentini D, Mahdavifar S, Reilly M, Ehrnst A, Maeurer M. Peptide Microarray-Based Identification of Mycobacterium tuberculosis Epitope Binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol. 2010;17:168-75. doi: 10.1128/CVI.00208-09. PubMed PMID: 19864486. PubMed Central PMCID: PMC2812096.
(11) Terasaki PI, MCClelland JD. Micro droplet assay of human serum cytotoxine nature. 1964;204:998-1000. PubMed PMID: 14248725.
(12) Mizrahi V. Genetic and tuberculosis, Cape Town, South Africa, 21 November. Tuber lung dis. 1997;78:71-174. PubMed PMID: 9713649.
(13) Axelsson-Robertson R, Weichold F, Sizemore D, Wulf M, Skeiky YAW, Sadoff J, et al. HLA-B alleles served as the dominant MHC class I restricting molecules for anti-Mtb TB10.4-specific [CD8.sup.+] T-cell responses measured in [CD8.sup.+] T cells from patients with pulmonary TB. Immunology. 2010;129:496-505. doi: 10.1111/j.1365-2567.2009.03201.x. PubMed Central PMCID: PMC2842496.
(14) Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;41:79-98. PubMed PMID: 2680563.
(15) Lewinsohn DA, Winata E, Swarbrick GM, Tanner KE, Cook MS, Null MD, et al. Immunodominant Tuberculosis CD8 Antigens Preferentially Restricted by HLA-B. PLoS Pathog. 2007;3:e127. doi: 10.1371/journal. ppat.0030127. PubMed Central PMCID: PMC2323292.
(16) Figueiredo JF, Rodrigues L, Deghaide NH, Donadi EA. HLA profile in patients with AIDS and tuberculosis. Braz J Infect Dis. 2008;12:278-80. PubMed PMID: 19030725.
(17) Vijaya Lakshmi V, Rakh SS, Anu Radha B, Hari Sai Prya V, Pantula V, Jasti S, et al. Role of HLA-B51 and HLA-B52 in susceptibility to pulmonary tuberculosis. Infect Genet Evol. 2006;6:436-9. PubMed PMID: 16563877.
(18) Uma H, Selvaraj P, Reetha AM, Xavier T, Prabhakar R, Narayanan PR. Influence of HLA-DR antigens on lymphocyte response to Mycobaterium tuberculosis culture filtrate antigens and mitogens in pulmonary tuberculosis. Tuber lung Dis. 1999;79:199-206. PubMed PMID: 10692987.
(19) Goldfeld AE, Delgado JC, Thim S, Bozon MV, Uglialoro AM, Turbay D, et al. Association of an HLA-DQ Allele With Clinical Tuberculosis. JAMA. 1998;279:226-28. PubMed PMID: 9438744.
(20) Kim HS, Park MH, Song EY, Park H, Kwon SY, Han SK, et al. Association of HLA-DR and HLA-DQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. Hum Immunol. 2005;66:1074-81. PubMed PMID: 16386650.
(21) Amirzargar AA, Yalda A, Hajabolbaghi M, Khosravi F, Jabbari H, Rezaei N, et al. The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2004;8:1017-21. PubMed PMID: 15305487.
Received: 29 August 2012
Revised: 29 September 2012
Accepted: 21 October 2012
Nidhal Abdulmohaimen Mohammed , PhD; Haitham Qassem , PhD; Farouk Hassen , PhD
 Department of Microbiology, Al-Nahrain College of Medicine, Al-Nahrain University, Baghdad, Iraq;
 Microbiologist, College of Pharmacy, Al Mustansiyria University, Baghdad, Iraq;
 Department of Microbiology, College of Medicine, Al Mustansiyria University, Baghdad, Iraq
Nidhal Abdulmohaimen Mohammed, PhD; Department of Microbiology, Alkadhymia Alnahrain College of Medicine, Baghdad, Iraq
Tel: +96 47901737256
Table 1: Observed numbers and percentage frequencies of human leukocyte antigen (HLA)-class I (A and B) alleles in the pulmonary tuberculosis patients and controls HLA Pulmonary Controls P value Alleles Tuberculosis (No=40) Patients (No =105) No % No % A1 20 19.1 7 17.5 0.523 A2 39 37.1 11 27.5 0.001 A3 20 19.1 8 20.0 0.001 A9 22 21.0 13 32.5 0.222 A10 18 17.1 12 30.0 0.395 A11 10 9.5 3 7.5 0.613 A19 25 23.8 5 12.5 0.221 A28 2 1.9 3 7.5 -- B5 7 6.7 10 25.0 B7 6 5.7 5 12.5 0.579 B8 23 21.9 5 12.5 0.057 B12 7 6.7 3 7.5 B13 1 1.0 4 10.0 -- B14 3 2.9 0 0.0 -- B15 1 1.0 0 0.0 -- B16 1 1.0 0 0.0 -- B17 3 2.9 2 5.0 -- B18 17 16.2 1 2.5 0.222 B21 9 8.6 3 7.5 0.371 B22 3 2.9 4 10.0 0.371 B27 1 1.0 3 7.5 0.325 B35 29 27.6 6 15.0 -- B37 1 1.0 0 0.0 0182 B40 1 1.0 0 0.0 -- B41 11 10.5 0 0.0 -- B48 2 1.9 1 2.5 -- B53 0 0.0 4 10.0 -- B73 1 1.0 0 0.0 -- Table 2. Observed numbers and percentage frequencies of human leukocyte antigen (HLA)-class II (DR and DQ) alleles in the pulmonary tuberculosis patients and controls HLA Pulmonary Controls P value Alleles Tuberculosis (No=40) Patients (No=105) No % No % DR1 54 51.4 4 10.0 0.001 DR2 28 26.7 13 32.5 0.028 DR3 30 28.6 6 15.0 0.102 DR4 28 26.7 9 22.5 0.589 DR5 11 10.5 3 7.5 0.242 DR6 6 5.7 3 7.5 0.141 DR7 14 13.3 8 20.0 0.266 DR8 2 1.9 7 17.5 0.005 DR10 4 3.8 3 7.5 0.222 DR53 6 5.7 5 12.5 0.303 DQ1 32 30.5 9 22.5 0.535 DQ2 24 22.9 8 20.0 0.898 DQ3 12 11.4 18 45.0 0.002 DQ4 9 8.6 9 22.5 0.081 Table 3: HLA alleles show a significant variation between the pulmonary tuberculosis patients and controls HLA OR EF or PF P Alleles B5 0.21 0.20 0.004 B18 7.53 0.14 0.018 DR1 9.53 0.46 1.9 x [10.sup.-6] DR8 0.09 0.16 0.002 DQ3 0.16 0.39 2.5 x [10.sup.-5] HLA Pc 95% C.I Alleles B5 N.S 0.064-0.69 B18 N.S 1.093-322.799 DR1 1.9 x [10.sup.-5] 3.056-38.922 DR8 0.02 0.009-0.522 DQ3 1.0 x [10.sup.-4] 0.060-0.409 OR: Odds ratio; EF: Etiological fraction; PF: Preventive fraction; P: Fisher's exact probability; Pc: Corrected P; C.I: Confidence interval; N.S: Not significant
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Mohammed, Nidhal Abdulmohaimen; Qassem, Haitham; Hassen, Farouk|
|Publication:||Iranian Journal of Medical Sciences|
|Date:||Mar 1, 2014|
|Previous Article:||Slums' access to and coverage of primary health care services: a cross-sectional study in Shiraz, a metropolis in Southern Iran.|
|Next Article:||Expression status of UBE2Q2 in colorectal primary tumors and cell lines.|